GlassScriptPhysician profile
Brian Christopher Daily
NPI 1427492503
$1,158.50
in general payments reported to CMS, 2019-2025
27 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $634 · 2020: $12.37 · 2021: $35.74 · 2022: $37.39 · 2023: $94.10 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $229.99 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $116.83 | 2019 | |
| Novo Nordisk INC | $106.28 | 2019-2023 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.77 | 2019-2025 | Xifaxan |
| Abbvie INC. | $52.65 | 2021-2022 | |
| Lilly USA, LLC | $42.45 | 2019-2025 | Mounjaro, Zepbound |
| Valeritas, INC. | $41.70 | 2019 | |
| Sumitomo Pharma America, INC. | $40.41 | 2025 | Gemtesa |
| Amarin Pharma, INC. | $39.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.16 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $36.65 | 2019 | |
| Merck Sharp & Dohme LLC | $35.82 | 2019 | |
| Amgen INC. | $33.86 | 2019 | |
| Glaxosmithkline, LLC. | $32.78 | 2019-2023 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $31.96 | 2019-2025 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.35 | 2019 | |
| Genentech USA, INC. | $27.58 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $20.20 | 2025 | Nuzyra |
| Astellas Pharma US INC | $17.97 | 2019 | |
| Ardelyx, INC. | $17.90 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $16.04 | 2025 | Voquezna |
| Organon LLC | $15.36 | 2023 | Nexplanon |
| Dexcom, INC. | $14.38 | 2025 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $14.13 | 2025 | Contrave |
| E.R. Squibb & Sons, L.L.C. | $12.13 | 2019 | |
| Horizon Therapeutics Plc | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Daily listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.